{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:46:17Z","timestamp":1772034377884,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T00:00:00Z","timestamp":1550880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10147-019-01401-5","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T04:38:45Z","timestamp":1550896725000},"page":"698-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib"],"prefix":"10.1007","volume":"24","author":[{"given":"Yasuyoshi","family":"Okamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7014-6812","authenticated-orcid":false,"given":"Nobuyuki","family":"Hinata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,23]]},"reference":[{"key":"1401_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/cncr.23518","volume":"113","author":"CJ Kane","year":"2008","unstructured":"Kane CJ, Mallin K, Ritchey J et al (2008) Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 113:78\u201383","journal-title":"Cancer"},{"issue":"4","key":"1401_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3109\/00365598709180784","volume":"21","author":"M Kjaer","year":"1987","unstructured":"Kjaer M, Iversen P, Hvidt V et al (1987) A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 21(4):285\u2013289","journal-title":"Scand J Urol Nephrol"},{"issue":"2","key":"1401_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S0022-5347(05)67889-5","volume":"163","author":"RJ Motzer","year":"2000","unstructured":"Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163(2):408\u2013417","journal-title":"J Urol"},{"key":"1401_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11523-017-0511-8","volume":"12","author":"JE Frampton","year":"2017","unstructured":"Frampton JE (2017) Pazopanib: a review in advanced renal cell carcinoma. Target Oncol 12:543\u2013554","journal-title":"Target Oncol"},{"issue":"1","key":"1401_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289\u2013296","journal-title":"J Clin Oncol"},{"key":"1401_CR6","unstructured":"Ljungberg B, Bensalah K, Bex A et al (2018) EAU guidelines on renal cell carcinoma 2018. \n                    http:\/\/uroweb.org\/guideline\/renal-cellcarcinoma\/\n                    \n                  . Accessed 15 Jun 2018"},{"key":"1401_CR7","unstructured":"National Comprehensive Cancer Network (2018) NCCN clinical practice guidelines in oncology: kidney cancer. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf\n                    \n                  . Accessed 15 Jun 2018"},{"key":"1401_CR8","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794\u20135799","journal-title":"J Clin Oncol"},{"key":"1401_CR9","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/cncr.23776","volume":"113","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Bukowski RM, Figlin RA et al (2008) Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113:1552\u20131558","journal-title":"Cancer"},{"key":"1401_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000430989","volume":"89","author":"MW Kattan","year":"2015","unstructured":"Kattan MW, Sternberg CN, Mehmud F et al (2015) Development and validation of a prognostic nomogram for progression-free survival in patients with advanced renal cell carcinoma treated with pazopanib. Oncology 89:235\u2013241","journal-title":"Oncology"},{"key":"1401_CR11","doi-asserted-by":"publisher","first-page":"6_suppl 455","DOI":"10.1200\/JCO.2017.35.6_suppl.455","volume":"35","author":"MW Kattan","year":"2017","unstructured":"Kattan MW, Winette TA, Powles T et al (2017) Development of a prognostic nomogram for liver toxicity in patients treated with pazopanib. J Clin Oncol 35:6_suppl 455\u2013455","journal-title":"J Clin Oncol"},{"issue":"6","key":"1401_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061\u20131068","journal-title":"J Clin Oncol"},{"issue":"18","key":"1401_CR13","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJMc1400731","volume":"370","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Hutson TE, McCann L et al (2014) Overall survival in renal cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370(18):1769\u20131770","journal-title":"N Engl J Med"},{"key":"1401_CR14","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/jjco\/hyq146","volume":"40","author":"Y Tomita","year":"2010","unstructured":"Tomita Y, Shinohara N, Yuasa T et al (2010) Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 40:1166\u20131172","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"1401_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ajco.12163","volume":"10","author":"S Lee","year":"2014","unstructured":"Lee S, Bang Y, Mainwaring P et al (2014) Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy. Asia Pac J Clin Oncol 10(3):237\u2013245","journal-title":"Asia Pac J Clin Oncol"},{"key":"1401_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/cncr.22827","volume":"110","author":"TK Choueiri","year":"2007","unstructured":"Choueiri TK, Garcia JA, Elson P et al (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543\u2013550","journal-title":"Cancer"},{"key":"1401_CR17","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/annonc\/mdf257","volume":"13","author":"S Negrier","year":"2002","unstructured":"Negrier S, Escudier B, Gomez F et al (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d\u2019Immunotherapie. Ann Oncol 13:1460\u20131468","journal-title":"Ann Oncol"},{"key":"1401_CR18","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1158\/1078-0432.CCR-11-0553","volume":"17","author":"J Manola","year":"2011","unstructured":"Manola J, Royston P, Elson P et al (2011) Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 17:5443\u20135450","journal-title":"Clin Cancer Res"},{"key":"1401_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.critrevonc.2017.11.009","volume":"121","author":"MA Climent","year":"2018","unstructured":"Climent MA, Mu\u00f1oz-Langa J, Basterretxea-Badiola L et al (2018) Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma. Crit Rev Oncol Hematol 121:45\u201350","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"1401_CR20","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.ejca.2015.03.019","volume":"51","author":"T Powles","year":"2015","unstructured":"Powles T, Bracarda S, Chen M et al (2015) Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. Eur J Cancer 51(10):1293\u20131302","journal-title":"Eur J Cancer"},{"key":"1401_CR21","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/jjco\/hyq073","volume":"40","author":"C Yoo","year":"2010","unstructured":"Yoo C, Kim JE, Lee JL et al (2010) The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 40:980\u2013985","journal-title":"Jpn J Clin Oncol"},{"issue":"Suppl 6","key":"1401_CR22","doi-asserted-by":"publisher","first-page":"Abstr 366","DOI":"10.1200\/jco.2013.31.6_suppl.366","volume":"31","author":"J Guo","year":"2013","unstructured":"Guo J, Jin J, Huang Y et al (2013) Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ). J Clin Oncol 31(Suppl 6):Abstr 366","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01401-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T19:29:45Z","timestamp":1582399785000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01401-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,23]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1401"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01401-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,23]]},"assertion":[{"value":"1 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}